Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at
Memorial Sloan Kettering Cancer Center, was awarded the Canada Gairdner International Award for his work on CD19 CAR T-cell therapy, along with Zelig Eshhar, PhD. Dr. Eshhar is a featured speaker in the documentary, “Living Drugs.”
“Dr. Sadelain has made seminal contributions to the discovery and clinical translation of CAR therapy. His research has primarily focused on human cell engineering and its potential to establish tumor immunity. His studies on receptor signaling led to the design of synthetic receptors for antigens, which he termed chimeric antigen receptors (CARs), the identification of CD19 as an effective CAR target in B cell malignancies, and the clinical implementation of CD19 CAR therapy. His group was the first to publish dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia treated with CD19 CAR T cells.”
excerpt from Article link: https://www.gairdner.org/winner/michel-sadelain